Article

Icotinib, an Effective Treatment Option for Patients With Lung Adenocarcinoma Harboring Compound EGFR L858R and A871G Mutation

2021-03-24

Abstract excerpt

Compound epidermal growth factor receptor ( EGFR ) mutations are defined as double or multiple independent mutations of the EGFR tyrosine kinase domain (TKD), in which an EGFR -tyrosine kinase inhibitor (TKI)-sensitizing mutation is identified together with a mutation of unclarified clinical significance. Lung adenocarcinoma with compound EGFR mutation shows poor clinical response to EGFR -TKIs. Kobayashi et al. r...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 16be68b1-b142-58d7-8be7-152c1d7bee17
DOI: 10.21203/rs.3.rs-331165/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Icotinib, an Effective Treatment Option for Patients With Lung Adenocarcinoma Harboring Compound EGFR L858R and A871G MutationDOI 10.21203/rs.3.rs-331165/v1Read

Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report.Semantic proximity Read

Status and progress of Icotinib in treatment of EGFR-mutant non-small cell lung carcinomaSemantic proximity Read

Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence.Semantic proximity Read

Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review.Semantic proximity Read

Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.Semantic proximity Read

First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience.Semantic proximity Read

Compound<i>EGFR</i>mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinomaSemantic proximity Read

Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study.Semantic proximity Read

Dacomitinib overcomes acquired resistance to osimertinib in advanced NSCLC patients with EGFR L718Q mutation: A two-case report.Semantic proximity Read

Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study.Semantic proximity Read

Icotinib: efficacy in different solid tumors and gene mutations.Semantic proximity Read

Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report.Semantic proximity Read